CDK4/6 Extends Reach Into Early-Stage Breast Cancer
CHICAGO — Adding ribociclib (Kisqali) to adjuvant endocrine therapy significantly improved invasive disease-free survival (iDFS) in patients with early-stage, high-risk breast cancer and hormone receptor (HR)-positive/HER2-negative disease, an interim analysis of a large phase III study found. In the NATALEE trial, which included patients with node-negative disease, the CKD4/6 inhibitor plus endocrine therapy combination resulted […]
Combo Treatment Extends Survival in HR+HER2- Advanced Breast Cancer
Adding the CDK 4/6 inhibitor ribociclib (Kisqali) to a first-line hormonal treatment prolonged survival by more than 1 year in postmenopausal women with HR-positive/HER2-negative (HR+HER2-) advanced breast cancer, according to results from the MONALEESA-2 trial. Final overall survival (OS) results showed that patients treated with ribociclib plus the aromatase inhibitor (AI) letrozole (Femara) achieved a […]